The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.
 
Yuqin Song
No Relationships to Disclose
 
Keshu Zhou
No Relationships to Disclose
 
Shuling Hou
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Fei Li
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Tienan Yi
No Relationships to Disclose
 
Ningjing Lin
No Relationships to Disclose
 
Xingchen Liu
No Relationships to Disclose
 
Wei Meng
Employment - ImmuneOnco Biopharmaceuticals
 
Zhenjiu Wang
Employment - ImmuneOnco Biopharmaceuticals
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
 
Jun Zhu
No Relationships to Disclose